Men get breast cancer, too. But they can't always access new drugs
Breast cancer is one of the most-researched illnesses in the world. But some men suffering from the disease say they’re not able to benefit from new research and treatments.
Sanofi Says FDA Approves Sarclisa for Treatment of Blood Cancer Patients
Sanofi said the Food and Drug Administration has approved Sarclisa as a first line combined treatment option for adult patients with newly diagnosed multiple myeloma who aren't eligible for autologous ...
MM&M2d
Daiichi Sankyo launches first DTC ad for Enhertu, representing shift toward patient-centric oncology campaigns
Daiichi Sankyo has launched a new direct-to-consumer (DTC) campaign for Enhertu — the first DTC effort for its oncology unit ...
Pharma Stock Roundup: FDA Approvals for LLY, MRK, AZN & JNJ Drugs
FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.
FiercePharma2d
Johnson & Johnson tacks on another NSCLC approval in pursuit of AstraZeneca's Tagrisso
Approvals are coming fast and furious for Johnson & Johnson’s Rybrevant as it is lining up to challenge the dominance of ...
Medscape2d
Conjugated Antibodies: Emerging Star in Ovarian Cancer Tx
Mirvetuximab soravtansine was the first ADC to show efficacy as a therapy for platinum-resistant ovarian cancer. Despite high ...
AstraZeneca: Poised for Growth with Promising Innovation Pipeline and Attractive Valuation
In a report released today, Eric Le Berrigaud from Stifel Nicolaus maintained a Buy rating on AstraZeneca (AZN – Research Report), with a ...
FiercePharma2d
Daiichi, AZ's first Enhertu DTC campaign kicks off during Thursday Night Football
As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...
AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation
The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial ...
Daiichi Sankyo-Merck's 'guided-missile' cancer drug meets main goal in late-stage trial
Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...
Business Insider4d
AstraZeneca: Strong Oncology Pipeline Fuels Growth and Outperformance – Buy Rating Endorsed
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The company sells branded drugs across several major therapeutic classes, including gastrointestinal ...